Stockscreener 앱 받기
16.71
0.12%
0.02
시간 외 거래:
16.71
Theravance Biopharma Inc 주식(TBPH)의 최신 뉴스
13,314 restricted shares listed for sale by TBPH (NASDAQ: TBPH) — Rule 144 notice - Stock Titan
Theravance Biopharma, Inc. 8-K Filing Details: Annual Meeting Results, Auditor Appointment, and Company Information (June 2026) - Minichart
Theravance Biopharma Shareholders Back Directors and Governance Plans - TipRanks
Theravance Biopharma (NASDAQ: TBPH) investors approve directors, auditor and pay plan - Stock Titan
TBPH News | THERAVANCE BIOPHARMA INC (NASDAQ:TBPH) - ChartMill
Theravance stock declines around 17% in three months: Here's why - MSN
Jones Trading Initiates Coverage of Theravance Biopharma (TBPH) with Buy Recommendation - MSN
TBPH Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineRevenue Surprise History - newsline.com
Avoiding Lag: Real-Time Signals in (TBPH) Movement - Stock Traders Daily
Theravance Biopharma (TBPH) Edges Lower Amid Mixed Technical Signals – Key Levels to MonitorEarnings Beat Stocks - newsline.com
JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Raises Target Price to $19 - Moomoo
Theravance Biopharma: Solid 1Q26 Execution, Cost Cuts, and YUPELRI Momentum Drive Buy Rating and Price Target Increase to $19 - TipRanks
Discipline and Rules-Based Execution in TBPH Response - Stock Traders Daily
Theravance Biopharma (TBPH) CEO has shares withheld to cover RSU taxes - Stock Titan
Theravance Biopharma (NASDAQ: TBPH) CFO has 8,670 shares withheld for RSU taxes - Stock Titan
Theravance Biopharma (TBPH) SVP has shares withheld for RSU taxes - Stock Titan
Theravance Biopharma (TBPH) SVP has 8,829 shares withheld for RSU tax - Stock Titan
Theravance Biopharma (TBPH) SVP uses 5,678 shares to cover tax bill - Stock Titan
Theravance Biopharma (TBPH) Q4 earnings and revenues lag estimates - MSN
Behavioral Patterns of TBPH and Institutional Flows - Stock Traders Daily
TradingKey - TradingKey
Are Options Traders Betting on a Big Move in Theravance Biopharma Stock? - TradingView
BTIG Maintains Theravance Biopharma (TBPH) Buy Recommendation - MSN
Here's why Theravance Biopharma (TBPH) is a strong momentum stock - MSN
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle - sharewise.com
BTIG Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Strong Revenue Growth and Strategic Collaborations Point to Promising Future - DirectorsTalk Interviews
Theravance Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Earnings Flash (TBPH) Theravance Biopharma, Inc. Reports Q1 Revenue $17.7M, vs. FactSet Est of $17.8M - marketscreener.com
Theravance Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Theravance Biopharma (NASDAQ: TBPH) slashes R&D after ampreloxetine trial miss - Stock Titan
Theravance Biopharma reports Q1 2026 revenue $17.7M, narrows net loss to $4.9M - TradingView
Ireland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth - TradingView
Theravance Bio: Q1 Earnings Snapshot - KTVB
Theravance (NASDAQ: TBPH) targets $60–70M cash flow after major restructuring - Stock Titan
Theravance Biopharma: Confident Will Achieve $100 Million Milestone Payment Associated With 2026 Trelegy Net Sales >TBPH - Moomoo
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update - ChartMill
MSN Money - MSN
(TBPH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Theravance's Q4 earnings and revenues miss estimates - MSN
Theravance Biopharma (NASDAQ:TBPH) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
2.60%
0.94%
자본화:
|
볼륨(24시간):